耐甲氧西林金黄色葡萄球菌流行现状及治疗策略的研究进展  

Research progress on epidemic situation and treatment strategy of Methicillin-Resistant Staphylococcus aureus

作　　者：于建梅 张媛媛[2] 王爽[2] 袁浩闻 李美佳 寇增强[2,4] YU Jian-mei;ZHANG Yuan-yuan;WANG Shuang;YUAN Hao-wen;LI Mei-jia;KOU Zeng-qiang(School of Public Health and Health Management,Shandong First Medical University(Shandong Academy of Medical Sciences),Taian,Shandong,271016,China)

机构地区：[1]山东第一医科大学(山东省医学科学院)公共卫生与健康管理学院,山东泰安271016 [2]山东省疾病预防控制中心 [3]山东大学齐鲁医学院公共卫生学院 [4]山东省预防医学科学院

出　　处：《预防医学论坛》2022年第9期717-720,共4页Preventive Medicine Tribune

基　　金：山东省重点研发计划(2017GSF218062);山东省医药卫生科技发展计划(2017WS105,202112071042)。

摘　　要：耐甲氧西林金黄色葡萄球菌(MRSA)是一种毒性较强的耐药菌,已经成为医院和社区内重要的感染来源之一,严重威胁人类健康。MRSA已对包括万古霉素在内的多种抗菌药物产生不同程度的耐药,甚至已经出现了多重耐药。面对MRSA抗药性增高,目前已研发出多种新型抗菌药物,并已有提取放线菌、纳米技术、反义技术、基因编辑技术等应用于抗MRSA药物研发,以期望能控制MRSA的感染。本文通过对MRSA的流行现状及目前的治疗策略进行综述,旨在为MRSA感染的预防与控制提供参考。Methicillin-resistant Staphylococcus aureus(MRSA) is a kind of highly toxic drug-resistant bacteria, which has become one of the important sources of infection in hospitals and communities, seriously threatening human health.MRSA has developed different degrees of resistance to many antimicrobial agents, including Vancomycin,and even multiple resistance has emerged.In the face of increasing MRSA resistance, several new antibacterial drugs have been developed, and extracted actinomycetes, nanotechnology, antisense technology and gene editing technology have been applied to the development of anti-MRSA drugs in the hope of controlling MRSA infections.This article reviews the epidemic situation and current treatment strategies of MRSA in order to provide reference for the prevention and control of MRSA infection.

关 键 词：耐甲氧西林金黄色葡萄球菌 抗菌药物 万古霉素 耐药 药物研发 

分 类 号：R378.11[医药卫生—病原生物学]